Tina Wahle
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Tina Wahle has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Alfonso Schiavi
IUF-Leibniz Research Institute for Environmental Medicine, Duesseldorf, Germany
1 shared publication - Bart De Strooper
Centre for Brain and Disease Research, Flanders Institute for Biotechnology (VIB), Leuven, Belgium
1 shared publication - Carlos Gerardo Dotti
Molecular Neuropathology Unit, Physiological and Pathological Processes Program, Centro de Biologia Molecular Severo Ochoa (CBM), CSIC-UAM, Madrid, Spain
1 shared publication - Claudia Bagni
Department of Fundamental Neurosciences, University of Lausanne, Lausanne, Switzerland
1 shared publication - Claudia Cirotti
Department of Biology, University of Rome “Tor Vergata”, Rome, Italy
1 shared publication - Daniela Barilà
Department of Biology, University of Rome “Tor Vergata”, Rome, Italy
1 shared publication
Latest Publications
- Open Access
- 14 October 2023
- Published by Springer Nature in Cell Death Discovery
- Vol. 9 (1) , 1-22
Abl depletion via autophagy mediates the beneficial effects of quercetin against Alzheimer pathology across species
Alzheimer’s disease is the most common age-associated neurodegenerative disorder and the most frequent form of dementia in our society. Aging is a complex biological process concurrently shaped by genetic, dietary and environmental factors and natural compounds are emerging for their beneficial effects against age-related disorders. Besides their antioxidant activity often described in simple model organisms, the molecular mechanisms underlying the beneficial effects of different dietary compounds remain however largely unknown. In the present study, we exploit the nematode Caenorhabditis elegans as a widely established model for aging studies, to test the effects of different natural compounds in vivo and focused on mechanistic aspects of one of them, quercetin, using complementary systems and assays. We show that quercetin has evolutionarily conserved beneficial effects against Alzheimer’s disease (AD) pathology: it prevents Amyloid beta (Aβ)-induced detrimental effects in different C. elegans AD models and it reduces Aβ-secretion in mammalian cells. Mechanistically, we found that the beneficial effects of quercetin are mediated by autophagy-dependent reduced expression of Abl tyrosine kinase. In turn, autophagy is required upon Abl suppression to mediate quercetin’s protective effects against Aβ toxicity. Our data support the power of C. elegans as an in vivo model to investigate therapeutic options for AD.
- 14 October 2023
- Published by Springer Nature in Cell Death Discovery
- Vol. 9 (1) , 1-22
Open AccessAbl depletion via autophagy mediates the beneficial effects of quercetin against Alzheimer pathology across species
Alzheimer’s disease is the most common age-associated neurodegenerative disorder and the most frequent form of dementia in our society. Aging is a complex biological process concurrently shaped by genetic, dietary and environmental factors and natural compounds are emerging for their beneficial effects against age-related disorders. Besides their antioxidant activity often described in simple model organisms, the molecular mechanisms underlying the beneficial effects of different dietary compounds remain however largely unknown. In the present study, we exploit the nematode Caenorhabditis elegans as a widely established model for aging studies, to test the effects of different natural compounds in vivo and focused on mechanistic aspects of one of them, quercetin, using complementary systems and assays. We show that quercetin has evolutionarily conserved beneficial effects against Alzheimer’s disease (AD) pathology: it prevents Amyloid beta (Aβ)-induced detrimental effects in different C. elegans AD models and it reduces Aβ-secretion in mammalian cells. Mechanistically, we found that the beneficial effects of quercetin are mediated by autophagy-dependent reduced expression of Abl tyrosine kinase. In turn, autophagy is required upon Abl suppression to mediate quercetin’s protective effects against Aβ toxicity. Our data support the power of C. elegans as an in vivo model to investigate therapeutic options for AD.